ReShape Lifesciences Soars 92.98% on AI Partnerships

On April 10, 2025, ReShape Lifesciences experienced a remarkable surge, rising 92.98% in pre-market trading, marking a significant milestone in its stock performance.

ReShape Lifesciences has recently partnered with Motion Informatics to distribute the FDA-cleared Stimel-03 platform, which combines AI, neuromodulation, and EMG biofeedback for stroke and injury recovery. This exclusive distribution deal is expected to enhance the company's portfolio and expand its reach in the rehabilitation technology market.

In addition to its partnership with Motion Informatics, ReShape Lifesciences has also secured an exclusive deal for neuromuscular rehabilitation devices in the U.S. This agreement aims to further strengthen the company's position in the market and provide innovative solutions for patients recovering from neuromuscular injuries.

ReShape Lifesciences has also expanded its U.S. reach through strategic partnerships and collaborations, further solidifying its presence in the obesity and metabolic disease management sector. The company's portfolio includes the FDA-approved Lap-Band® System, which has been a key contributor to its success in this market.

Despite these positive developments, ReShape Lifesciences has faced challenges, including a delay in its Form 10-K filing for 2024. The company cited the need for more time to complete its financial statements, which may have contributed to some uncertainty among investors. However, the recent partnerships and expansions are expected to mitigate these concerns and drive future growth for the company.